STOK vs. PHAT, ORIC, AVBP, CDMO, HROW, SLN, SVRA, OLMA, ZYME, and CMPS
Should you be buying Stoke Therapeutics stock or one of its competitors? The main competitors of Stoke Therapeutics include Phathom Pharmaceuticals (PHAT), ORIC Pharmaceuticals (ORIC), ArriVent BioPharma (AVBP), Avid Bioservices (CDMO), Harrow (HROW), Silence Therapeutics (SLN), Savara (SVRA), Olema Pharmaceuticals (OLMA), Zymeworks (ZYME), and COMPASS Pathways (CMPS). These companies are all part of the "pharmaceutical preparations" industry.
Phathom Pharmaceuticals (NASDAQ:PHAT) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.
In the previous week, Phathom Pharmaceuticals had 5 more articles in the media than Stoke Therapeutics. MarketBeat recorded 7 mentions for Phathom Pharmaceuticals and 2 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 0.55 beat Phathom Pharmaceuticals' score of 0.33 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.
Phathom Pharmaceuticals presently has a consensus price target of $22.00, suggesting a potential upside of 109.92%. Stoke Therapeutics has a consensus price target of $20.57, suggesting a potential upside of 37.42%. Given Stoke Therapeutics' higher possible upside, research analysts clearly believe Phathom Pharmaceuticals is more favorable than Stoke Therapeutics.
Stoke Therapeutics has higher revenue and earnings than Phathom Pharmaceuticals. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 24.1% of Phathom Pharmaceuticals shares are owned by company insiders. Comparatively, 11.3% of Stoke Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Stoke Therapeutics' return on equity of 0.00% beat Phathom Pharmaceuticals' return on equity.
Phathom Pharmaceuticals has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.
Stoke Therapeutics received 31 more outperform votes than Phathom Pharmaceuticals when rated by MarketBeat users. Likewise, 72.99% of users gave Stoke Therapeutics an outperform vote while only 67.65% of users gave Phathom Pharmaceuticals an outperform vote.
Summary
Stoke Therapeutics beats Phathom Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Stoke Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Stoke Therapeutics Competitors List
Related Companies and Tools
